NEWS FROM THE NHLBI
Cardiovascular Disease in Adult and Pediatric HIV/AIDS
Cheryl L. McDonald, MD* and
Jonathan R. Kaltman, MD
National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, Bethesda, Maryland
Manuscript received April 23, 2009;
accepted May 6, 2009.
* Reprint requests and correspondence: Dr. Cheryl L. McDonald, AIDS Coordinator, Division of Cardiovascular Diseases, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 8114, Bethesda, Maryland 20892-7940 (Email: mcdonalc{at}nhlbi.nih.gov).
Key Words: HIV/AIDS • cardiovascular disease • highly active antiretroviral therapy • dyslipidemia • drug toxicity
|
Abbreviations and Acronyms
| | ART = antiretroviral therapy | | AZT = zidovudine | | CVD = cardiovascular disease | | HAART = highly active antiretroviral therapy | | HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome | | LV = left ventricular | | NHLBI = National Heart, Lung, and Blood Institute | | PAH = pulmonary arterial hypertension | | PPH = primary pulmonary hypertension |
|
Since it was first recognized clinically in 1981, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) has gone from a fatal syndrome to a chronic disease in persons receiving highly active antiretroviral therapy (HAART). Although the first antiretroviral agent, zidovudine (AZT), was introduced into the market in 1987, the era of HAART really began after the marketing approval of the first protease inhibitor in December 1995. Much has been reported about the relationship between HAART and cardiovascular disease (CVD), but it is this combination antiretroviral therapy that has allowed the overall mortality associated with HIV to decline dramatically and life expectancy to increase to the point where CVD-related deaths now represent an increasing proportion of the deaths in HIV-infected patients.
Even before the era of HAART, researchers noted that untreated HIV-infected patients had altered lipid profiles, including lowered high-density lipoprotein and low-density lipoprotein cholesterol levels, elevated triglyceride levels, and anthropomorphic changes such as increased visceral fat and decreased subcutaneous fat (1,2). With the widespread use of HAART, the contribution of drug-related metabolic and anthropometric alterations to an increased risk for CVD took on an even greater significance. Several studies in adult populations have provided evidence of an association between HIV infection and its treatment and CVD; these studies include retrospective studies such as the Kaiser Permanente Registry study (3), prospective observational cohort studies such as the DAD (Data Collection of Adverse Events of Anti-HIV Drugs) study (4,5), and prospective randomized clinical trials such as the SMART (Strategies for Management of Antiretroviral Therapy) trial (6). Although myriad class- and nonclass-specific effects on lipid profiles, glucose levels, insulin sensitivity, and body composition have been reported with various antiretroviral agents, there is no question that the use of HAART to ensure adequate viral suppression is paramount to the successful clinical management of HIV-infected patients.
The currently available evidence from various studies suggests that although the overall cardiovascular event rate is low, there is an excess risk of cardiovascular events in HIV-infected persons compared with non–HIV-infected persons. Evidence suggests that HIV-infected patients on HAART regimens are at increased risk of dyslipidemia, ischemic heart disease (7), and myocardial infarction, particularly if the HAART regimen contains a protease inhibitor (8,9). While lipid-lowering therapies are a routine element of cardiovascular risk reduction in the general population, HIV-infected patients may not be receiving lipid-lowering therapies even when indicated. A recent report showed that among patients meeting the NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) criteria (10), there was a disparity in receipt of lipid-lowering agents among HIV-infected veterans compared with non–HIV-infected veterans (15.4% vs. 37.9%, p < 0.01) (11). In 2003, the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group issued an updated version of "Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus-Infected Adults Receiving Antiretroviral Therapy" (12). Patients infected with HIV may have special issues, such as coinfection with hepatitis C, seemingly complicated medication regimens, unusually high triglyceride levels, or the need to gain weight yet achieve lower lipid levels; but, the approach to the management of their dyslipidemia is essentially the same as that for the general population, including starting with nondrug and dietary modalities. If lipid-lowering agents are indicated, navigating the sea of potential drug-drug interactions with the HAART regimen can be challenging, but that should not preclude the use of drugs such as statins or fibrates for HIV-infected patients. Getting to target low-density lipoprotein goals can and should be accomplished by a cardiologist working closely with an infectious diseases specialist (13).
Antiretroviral drugs are the cornerstone of HIV/AIDS management, and they may be associated with insulin resistance and dyslipidemia, but those are not the only factors likely involved in the increased CVD risk seen in HIV-infected patients. Traditional risk factors, such as increased rates of smoking, may be increased in these patients; HIV itself may affect traditional risk factors, including lipid profiles; and/or there may be increased underlying inflammation or endothelial dysfunction. How HIV affects the heart and vasculature as a whole in the presence of antiretroviral therapy (ART) is not fully known, but left ventricular (LV) dysfunction is clinically common, and pulmonary arterial hypertension can occur in 1 of every 200 HIV-positive adults, most often in patients without advanced HIV disease. In contrast to primary pulmonary hypertension (PPH), in which there is a female predominance, males are more affected by pulmonary arterial hypertension (PAH) associated with HIV infection (HIV-PAH). Although HIV-PAH shares several clinical and pathological features with PPH, it has decreased 1-year survival rates (51%) compared to rates in a National Institutes of Health registry for PPH (68%) (14). Patients with HIV-PAH have worse survival than do HIV-infected patients without PAH and often die from conditions related to the pulmonary hypertension, not the HIV infection per se. Therefore, prompt diagnosis and initiation of specific therapy such as a prostacyclin (epoprostenol) or the dual endothelin receptor antagonist bosentan is crucial (15). Isolated diastolic dysfunction may be an early sign of CVD in both the general population and HIV-infected patients. A recent, albeit small, study reported an unexpectedly high prevalence of diastolic dysfunction (37%) in a cohort of young (median age 38 years), asymptomatic HIV-infected patients at otherwise low risk for CVD (16). Consequently, although there are currently no recommendations for routine screening echocardiograms of this population, these data suggest such additional evaluations may be warranted for particular patients.
Research conducted before the HAART era demonstrated that HIV infection itself can cause nonatherosclerotic structural and functional injury to the heart and vasculature. In 1 of the first reports of cardiac disease in HIV-infected children, Lipshultz et al. (17) reported abnormalities of LV shortening, afterload, and contractility. Pericardial effusion, arrhythmias, and pathologic evidence of pericarditis, myocarditis, and inflammation of the conduction system were also observed. To address the high rates of cardiac complications seen in the HIV/AIDS epidemic, the National Heart, Lung, and Blood Institute (NHLBI) initiated the P2C2 HIV (Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection) study in 1990 (18). The P2C2 HIV study was a prospective, observational study that enrolled HIV-infected children from 1990 to 1993 with follow-up to 10 years of age. The study documented cardiac complications as a common feature of HIV disease in children. The 5-year cumulative incidence of depressed shortening fraction was 28%, the incidence of LV end-diastolic dilation was 22%, and the incidence of heart failure and/or use of cardiac medications was 29% (19). Decreased LV shortening and increased LV wall thickness were found to be predictive of mortality even after adjusting for CD4 count and encephalopathy (20).
One of the great successes of HAART is the significant decrease in vertical transmission of HIV from mother to child, but this has led to an increasing cohort of ART-exposed, HIV-negative children. Recent evidence suggests an important role of ART exposure itself in contributing to cardiac disease. The P2C2 HIV study documented diminished LV shortening and contractility at birth in HIV-negative infants born to HIV-positive mothers, suggesting that the in utero environment plays an important role in postnatal cardiovascular function. Animal model data have subsequently indicated that nucleoside analog reverse transcriptase inhibitors have a toxic effect on mitochondrial function (21). Further, human studies have demonstrated a depletion of mitochondrial DNA and elevated plasma lactate levels in HIV-negative infants born to zidovudine-treated, HIV-positive mothers (22). Taken together, these data suggest potential cardiotoxic effects of ART exposure in utero. Recently, more direct evidence for this association was provided by the CHAART-I (Cardiac Status of HAART Exposed Infants of HIV-Infected Mothers) study, in which serial echocardiograms from HIV-negative infants born to ART- or HAART-treated, HIV-positive mothers were compared to HIV-negative infants born to HIV-positive mothers who did not receive perinatal ART or HAART. A preliminary report from that study indicated that fetal exposure to ART/HAART was associated with progressive reductions in LV mass and septal wall thickness (23).
The NHLBI provides cofunding for the Eunice Kennedy Shriver National Institute of Child Health and Human Development-sponsored PHACS (Pediatric HIV/AIDS Cohort Study) network (24). This network, established in 2005, seeks to advance our understanding of the long-term safety of fetal and infant exposure to prophylactic ART and the effects of perinatally acquired HIV infection in adolescents. The network currently supports 2 prospective, observational cohort studies—the Surveillance Monitoring for ART Toxicities (SMARTT) study and the Adolescent Master Protocol (AMP) study—both with significant cardiovascular components.
The SMARTT study (not to be confused with the SMART study in adults) follows the ART-exposed, but HIV-uninfected infants and children born to HIV-infected mothers to evaluate them for conditions and diagnoses potentially related to in utero and infantile exposure to antiretroviral therapies. The study will identify abnormalities in cardiac function related to ART and/or HIV exposure and examine the utility of serum biomarkers as surrogates of cardiac dysfunction.
The AMP cohort consists of perinatally exposed, HIV-infected children between the ages of 7 and 16 years and a comparison group of perinatally exposed, HIV-uninfected children. The goal of the study is to evaluate the impact of HIV infection and ART on pre-adolescents and adolescents with perinatal HIV infection. Cardiac function will be evaluated by echocardiography to estimate the prevalence of structural and functional abnormalities in this contemporary cohort of HIV-infected youths.
Recently published work has demonstrated that, similar to use in adults, the use of protease inhibitors in HIV-infected children is significantly correlated with elevated triglyceride and low-density lipoprotein cholesterol levels and with reduced high-density lipoprotein cholesterol levels (25). What this means in terms of cardiovascular risk for HIV-infected children, in the face of life-long antiretroviral therapy, is unknown.
A State of the Science Conference was convened in Chicago in June 2007 to examine the important unanswered questions surrounding the pathogenesis, detection, and treatment of CVD in HIV-infected persons (26). After this conference, the NHLBI issued a request for applications for research into the mechanisms and management of cardiovascular and metabolic complications of HIV/AIDS. The NHLBI awarded grants to 8 primary research sites and a clinical coordinating center, representing a spectrum of HIV-infected patients and controls including men and women, children, persons with long-standing infection, and newly diagnosed and/or treatment-naïve patients. Some of the areas under investigation in this program include the following: the role of oxidative stress and inflammation in elevated CVD risk; the effect of antiretroviral therapies on endothelial function and atherosclerosis progression; immune, inflammatory, coagulation, and lipid alterations as mediators of increased atherosclerosis; and assessments of vascular dysfunction due to HIV itself and metabolic parameters. The various studies include standard and novel imaging techniques as well as measurements of endothelial function. The awardees have worked together closely to develop a core set of, and standardized approaches to, laboratory evaluations. The results from these studies are sure to add to our knowledge of CVD and its management in HIV/AIDS, with the possibility for advancing our understanding of CVD in general.
The NHLBI encourages the continued partnership of basic and clinical cardiovascular and infectious diseases researchers in their effort to tackle the difficult and still unanswered questions of CVD in HIV/AIDS.
 |
Footnotes
|
|---|
Drs. McDonald and Kaltman are Medical Officers in the Division of Cardiovascular Sciences, NHLBI.
|
References
|
|---|
1. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome J Clin Endocrinol Metab 1992;74:1045-1052.[Abstract]2. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects J Acquir Immune Defic Syndr Human Retrovirol 1999;20:228-237.[Web of Science][Medline] 3. Klein D, Hurley LB, Quesenberry Jr. CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-477.[Web of Science][Medline] 4. Friis-Møller N, Weber R, Reiss P, et al. DAD Study Group Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193.[CrossRef][Web of Science][Medline] 5. Friis-Møller N, Sabin CA, Weber R, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 2003;349:1993-2003.[CrossRef][Web of Science][Medline] 6. El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 2006;355:2283-2296.[CrossRef][Medline] 7. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study Clin Infect Dis 2007;44:1625-1631.[Abstract/Free Full Text] 8. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab 2007;92:2506-2512.[Abstract/Free Full Text] 9. Friis-Møller N, Reiss P, Sabin CA, et al. DAD Study Group Class of antiretroviral drugs and the risk of myocardial infarction N Engl J Med 2007;356:1723-1735.[CrossRef][Medline] 10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 2001;285:2486-2497.[Free Full Text] 11. Freiberg MS, Leaf DA, Goulet JL, et al. The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication J Gen Intern Med 2009;24:334-340.[CrossRef][Web of Science][Medline] 12. Dubé MP, Stein JH, Aberg JA, et al. Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clin Infect Dis 2003;37:613-627.[Free Full Text] 13. Stein JH. Managing cardiovascular risk in patients with HIV infection J Acquir Immune Defic Syndr 2005;38:115-123.[CrossRef][Web of Science][Medline] 14. Seoane L, Shellito J, Welsh D, deBoisblanc BP. Pulmonary hypertension associated with HIV infection South Med J 2001;94:635-639.[Web of Science][Medline] 15. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management AIDS 2008;22(Suppl 3):55-62.[CrossRef] 16. Nayak G, Ferguson M, Tribble DR, et al. Cardiac diastolic dysfunction is prevalent in HIV-infected patients AIDS Patient Care STDs 2009Mar 13 [E-pub ahead of print]. 17. Lipshultz SE, Chanock S, Sanders SP, Colan SD, Perez-Atayde A, McIntosh K. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children Am J Cardiol 1989;63:1489-1497.[CrossRef][Web of Science][Medline] 18. The P2C2 HIV Study Group The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus infection study: design and methods J Clin Epidemiol 1996;49:1285-1294.[CrossRef][Web of Science][Medline] 19. Starc TJ, Lipshultz SE, Easley KA, et al. Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study J Pediatr 2002;141:327-334.[CrossRef][Web of Science][Medline] 20. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter study Circulation 2000;102:1542-1548.[Abstract/Free Full Text] 21. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD, Working Group 3 Effects of HIV infection and antiretroviral therapy on the heart and vasculature Circulation 2008;118:e36-e40.[Free Full Text] 22. Zareba KM, Lavigne JE, Lipshultz SE. Cardiovascular effects of HAART in infants and children of HIV-infected mothers Cardiovasc Toxicol 2004;4:271-279.[CrossRef][Medline] 23. Lipshultz SE, Shearer WT, Thompson B, et al. Antiretroviral therapy (ART)-associated cardiotoxicity in uninfected by ART-exposed infants born to HIV-infected women: the prospective NHLBI CHAART-I study (abstr). Paper presented at: Annual Meeting of the Pediatric Academic Society; San Francisco, CA; April 29 to May 2, 2006. 24. National Institutes of HealthNational Institute of Child Health and Human Development Pediatric HIV/AIDS Cohort Study (PHACS) http://www.nichd.nih.gov/research/supported/phacs.cfm 2004Accessed April 1, 2009. 25. Miller TL, Orav EJ, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1 J Pediatr 2008;153:491-497.[CrossRef][Web of Science][Medline] 26. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the Science Conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008;118:198-210.[Free Full Text]
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A27.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. A. Butt, C.-C. Chang, L. Kuller, M. B. Goetz, D. Leaf, D. Rimland, C. L. Gibert, K. K. Oursler, M. C. Rodriguez-Barradas, J. Lim, et al.
Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease
Arch Intern Med,
April 25, 2011;
171(8):
737 - 743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
References